A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

• ClinicalTrials.gov Identifier: NCT03495817
• Recruitment Status: Completed
• First Posted: April 12, 2018
• Results First Posted: December 9, 2020
• Last Update Posted: December 9, 2020
• Sponsor: Aclaris Therapeutics, Inc.
• Information provided by (Responsible Party): Aclaris Therapeutics, Inc.

Study Description

Brief Summary:

Open label study to assess safety, tolerability, and efficacy of ATI-50002 in male and female subjects with androgenetic alopecia.

Condition or disease	Intervention/treatment	Phase
Androgenetic Alopecia	Drug: ATI-50002	Phase 2

Detailed Description:

This is an open-label study designed to evaluate the safety and efficacy of ATI-50002 Topical Solution in male and female subjects with androgenetic alopecia.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 31 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
• Actual Study Start Date: March 22, 2018
• Actual Primary Completion Date: October 15, 2019
• Actual Study Completion Date: October 30, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: ATI-50002 Topical Solution; This is an open-label phase 2 study designed to evaluate the safety and efficacy of ATI- 50002 Topical Solution, 0.46% in male and female subjects with androgenetic alopecia. Subjects will be required to apply ATI-50002 study medication to their scalp twice a day for a total of 26 weeks.	Drug: ATI-50002; ATI-50002 Topical Solution

Outcome Measures

Primary Outcome Measures :

1. Mean Change From Baseline in Target Area Hair Count (TAHC) [ Time Frame: Baseline to 26 Weeks ]
   Target Area Hair Count will measure the hairs/cm2 on a subject's head. Higher values represent better outcomes.

Secondary Outcome Measures :

1. Mean Change From Baseline in Target Area Hair Count (TAHC) [ Time Frame: Baseline to 52 Weeks ]
   Target Area Hair Count will measure the hairs/cm2 on a subject's head. Higher values represent better outcomes.
2. Mean Change From Baseline in Cumulative Target Area Hair Width (TAHW) [ Time Frame: Baseline to 26 Weeks ]
   Target Area Hair Width (TAHW) will measure the cumulative width of hair in the subject's target area. Higher values represent better outcomes.
3. Mean Change From Baseline in Cumulative Target Area Hair Width (TAHW) [ Time Frame: Baseline to 52 Weeks ]
   Target Area Hair Width (TAHW) will measure the cumulative width of hair in the subject's target area. Higher values represent better outcomes.
4. Investigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale [ Time Frame: Baseline to 26 Weeks ]
   Investigators will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.
5. Investigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale [ Time Frame: Baseline to 52 Weeks ]
   Investigators will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.
6. Subject Self-Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale [ Time Frame: Baseline to 26 Weeks ]
   Subjects will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.
7. Subject Self-Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale [ Time Frame: Baseline to 52 Weeks ]
   Subjects will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.
8. Change From Baseline in Androgenetic Alopecia (AGA) Using the Norwood-Hamilton Scale [ Time Frame: Baseline to 26 Weeks ]

   Measure Description: Subject's level of hair loss at baseline based on the Norwood Hamilton Scale for male subjects.

   Type I: Minimal or no recession of the hairline Type II: Triangular areas of recession at the frontotemporal hairline Type III: Deep symmetrical recession at the temples are bare or only sparsely covered by hair Type IV: Frontotemporal recession is more severe than in Type III with sparse or no hair on the vertex Type V: The vertex hair loss region is separated from the frontotemporal region but is less distinct Type VI: Sparse hair remaining Type VII: The most severe form of hair loss. Lower scores represent better outcomes.

9. Change From Baseline in Androgenetic Alopecia (AGA) Using the Norwood-Hamilton Scale [ Time Frame: Baseline to 52 Weeks ]

   Measure Description: Subject's level of hair loss at baseline based on the Norwood Hamilton Scale for male subjects.

   Type I: Minimal or no recession of the hairline Type II: Triangular areas of recession at the frontotemporal hairline Type III: Deep symmetrical recession at the temples are bare or only sparsely covered by hair Type IV: Frontotemporal recession is more severe than in Type III with sparse or no hair on the vertex Type V: The vertex hair loss region is separated from the frontotemporal region but is less distinct Type VI: Sparse hair remaining Type VII: The most severe form of hair loss. Lower scores represent better outcomes.

10. Change From Baseline in Androgenetic Alopecia (AGA) Using the Sinclair Scale [ Time Frame: Baseline to 26 Weeks ]

    Treating investigators will be required to rate the subject's level of hair loss at baseline based on the Sinclair scale for women.

    Grade 1: is normal. This pattern is found in all girls prior to puberty but in only forty-five percent of women aged eighty or over.

    Grade 2: shows a widening of the central part. Grade 3: shows a widening of the central part and thinning of the hair on either side of the central part.

    Grade 4: reveals the emergence of a diffuse hair loss over the top of the scalp.

    Grade 5: indicates advanced hair loss. Lower grades represent better outcomes.

11. Change From Baseline in Androgenetic Alopecia (AGA) Using the Sinclair Scale [ Time Frame: Baseline to 52 Weeks ]

    Treating investigators will be required to rate the subject's level of hair loss at baseline based on the Sinclair scale for women.

    Grade 1: is normal. This pattern is found in all girls prior to puberty but in only forty-five percent of women aged eighty or over.

    Grade 2: shows a widening of the central part. Grade 3: shows a widening of the central part and thinning of the hair on either side of the central part.

    Grade 4: reveals the emergence of a diffuse hair loss over the top of the scalp.

    Grade 5: indicates advanced hair loss. Lower grades represent better outcomes.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 50 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Male subjects and non-pregnant, non-nursing female subjects 18-50 years of age with a clinical diagnosis of androgenetic alopecia.

Subjects willing to agree to have a small circle of hair clipped to approx. 1mm in length on their balding spot.

Subjects willing to agree to have a permanent dot tattoo applied to their scalp to mark the center of the identified target area.

Subjects must agree to maintain the same hair style and hair care regimen during the study.

Exclusion Criteria:

Females who are nursing, pregnant, or planning to become pregnant for the duration of the study and up to 30 days after the last application of study medication.

Clinical diagnosis of alopecia areata or other non AGA forms of alopecia. Scalp hair loss on the treatment area, due to disease, injury or medical therapy.

Active skin disease of the scalp (such as psoriasis or seborrheic dermatitis) or a history of skin disease on the scalp that in the opinion of the investigator would interfere with the study assessments or efficacy or safety.

Contacts and Locations

Locations

United States, Colorado

Aclaris Investigational Site

Denver, Colorado, United States, 80210

United States, Oregon

Aclaris Investigational Site

Portland, Oregon, United States, 97210

United States, Texas

Aclaris Investigational Site

Austin, Texas, United States, 78759

Sponsors and Collaborators

Aclaris Therapeutics, Inc.

Investigators

• Study Chair: Stuart Shanler, MD; Aclaris Therapeutics, Inc.

  Study Documents (Full-Text)

Documents provided by Aclaris Therapeutics, Inc.:

Study Protocol  [PDF] January 24, 2019

Informed Consent Form  [PDF] October 15, 2018

Statistical Analysis Plan  [PDF] April 23, 2019

More Information

• Responsible Party: Aclaris Therapeutics, Inc.
• ClinicalTrials.gov Identifier: NCT03495817
• Other Study ID Numbers: ATI-50002-AGA-201
• First Posted: April 12, 2018
• Results First Posted: December 9, 2020
• Last Update Posted: December 9, 2020
• Last Verified: November 2020

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Alopecia; Alopecia Areata; Hypotrichosis; Hair Diseases; Skin Diseases; Pathological Conditions, Anatomical